NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Palatin Technologies, Inc. (PTN) Stock Analysis

Palatin Technologies, Inc. (PTN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PTN

$12.70

−$0.38 (−2.91%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PTN with… →

PTN Key Statistics

As of Sep 4, 2026
Trading
Open
$12.83
Previous Close
$13.08
Day's Range
12.49–13.48
52-Week Range
5.61–31.00
Volume
257.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.04
Valuation
Market Cap
$22.60M
P/E Ratio
115.45
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.62
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.75
EPS (ttm)Profit attributable to each share over the last twelve months.
0.11
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$17.31M
Profit marginThe share of revenue left as profit after all costs and taxes.
−48.50%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.78M
1-Year Return
+41.11%
Dividend and dates
Avg Volume
40.59K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PTN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−17.43%
2025−72.29%
2024−72.11%
2023+55.47%
2022−79.92%
2021−25.00%
2020−12.82%
2019+9.86%
2018−17.44%
2017+68.63%
2016 (partial year)−10.53%

As of September 4, 2026.

PTN Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$17.31M—
2024$4.49M−$29.74M−662.3%
2023$4.85M−$24.04M−495.2%
2022$1.47M−$36.20M−2465.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00$0.00−$22.71M−$17.31M—
2024$4.49M$4.39M−$30.28M−$29.74M−662.3%
2023$4.85M$4.44M−$33.49M−$24.04M−495.2%
2022$1.47M$1.25M−$36.59M−$36.20M−2465.1%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

PTN Valuation vs Biotechnology Median

Median of 656 stocks
MetricPTNBiotechnology medianvs median
P/E115.4512.579.2x the median
P/S ratio1.7515.260.1x the median
Profit margin−48.50%0.00%48.5 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Palatin Technologies, Inc. (PTN) at $22.60M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 29.

Over the past 52 weeks the price has ranged from $5.61 to $31.00. The most recent close on file for PTN is $12.70, dated September 4, 2026. That is −$0.38 (−2.91%) against the previous close. The latest close sits 126.38% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. Against the prior fiscal year total of $4.49M, that is a change of −100.00%. The same year closed with a net loss of $17.31M. Profit margin runs at −48.5%. That is 48.5 percentage points below the Biotechnology median of 0%. Trailing earnings per share are 0.11.

Across the 4 fiscal years on file, revenue moves from $1.47M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 115.45 times earnings. That is 9.2 times the Biotechnology median of 12.57. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.62. Measured against sales, the shares trade at 1.75 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +41.11%. Measured over 10 years, that is −32.40% a year compounded. Beta against the wider market is reported at −0.04. Daily returns over the trailing 10 years annualize to a volatility of 106.94%.

Growth & Income

No dividend is on file for PTN.

2026 is still running; the price is −17.43% year to date. Across the complete calendar years on file, 2017 returned +68.63% and 2022 returned −79.92%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Palatin Technologies, Inc. (PTN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Palatin Technologies, Inc. PTN $22.60M 115.5
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Palatin Technologies, Inc. trades at a P/E of 115.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Palatin Technologies, Inc.

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Visit website →